Eton Pharmaceuticals, Inc. — Q3 2019 Form 10-Q
Reporting period: Three and nine months ended September 30, 2019. Unaudited; financial amounts below are in thousands of dollars except per-share data and share counts.
Business context and results
Eton is a specialty pharmaceutical company developing and commercializing prescription products, primarily through the FDA’s 505(b)(2) pathway. It reported no revenue in Q3 2019. Nine-month revenue of $500 came from selling EM-100 product rights to Bausch; the agreement also provides for a $1,500 milestone upon first commercial sale and royalties on U.S. net sales for ten years from that sale.
| Metric | Three months ended Sept. 30 | Nine months ended Sept. 30 |
|---|---|---|
| Revenue, 2019 / 2018 | $0 / $0 | $500 / $0 |
| Research and development, 2019 / 2018 | $3,418 / $1,544 | $11,322 / $4,525 |
| General and administrative, 2019 / 2018 | $1,624 / $830 | $5,123 / $3,510 |
| Operating loss, 2019 / 2018 | $(5,042) / $(2,374) | $(15,945) / $(8,035) |
| Net loss, 2019 / 2018 | $(4,965) / $(2,910) | $(15,624) / $(9,010) |
| Net loss per share, basic and diluted | $(0.28) / $(0.65) | $(0.88) / $(2.40) |
Gross margin is not meaningful for Q3 because there was no revenue; the filing does not present a clear gross-margin measure for the nine-month period. Lower loss per share versus 2018 reflects a substantially higher weighted-average share count following the November 2018 IPO and the preferred-stock conversion, despite larger total losses.
Cash flow, balance sheet and liquidity
- At September 30, 2019, cash and cash equivalents were $11,777, down from $26,735 at December 31, 2018. Total assets were $13,507; total liabilities were $1,159, including $182 of operating lease liabilities. The filing reports no borrowings at quarter-end.
- For the first nine months, operating cash use was $14,178, investing cash use was $1,062, and financing cash provided was $282. Cash declined by $14,958. Investing cash use primarily reflected laboratory-related capital expenditures.
- Management said existing cash and expected Biorphen revenue were expected to fund operating expenses and capital expenditures for at least 12 months from issuance of the financial statements. This was based on assumptions about sales and spending; the company cautioned that resources could be used sooner and future financing might be needed.
Changes, outlook and risks
- Compared with 2018, nine-month R&D expense rose $6,797, primarily due to licensing and milestone costs for product candidates, including DS-200, ET-202, ET-203 and ET-104, and higher personnel and laboratory costs. Q3 R&D included $2,060 in ET-105 milestone spending.
- Nine-month G&A rose $1,613, reflecting increased staffing, public-company costs, initial marketing and distribution setup, partly offset by lower stock-based consulting fees. Management anticipated further G&A growth to support commercialization and business expansion.
- The company received FDA approval for Biorphen on October 21, 2019, after quarter-end, and expected significant revenue-generating activity to begin in late 2019 and beyond. Commercial results, timing and product uptake remained uncertain.
- On November 13, 2019, after quarter-end, Eton entered a secured five-year credit agreement with SWK providing up to $10,000. It drew $5,000 at closing, with further borrowing contingent on product approvals. The loan bears interest at three-month LIBOR plus 10%, subject to a 2% floor; includes a 5% exit fee, a $3,000 minimum-cash requirement and quarterly principal payments of 4%. Warrants, covenants and limits on additional indebtedness also apply.
- Development, FDA review, commercialization, financing availability and the ability to manage spending are material uncertainties. The company disclosed no material change to the risk factors in its 2018 Form 10-K, no pending or threatened litigation with a material expected impact, and effective disclosure controls.
- Related-party arrangements include product agreements with entities affiliated with the CEO and transactions with Harrow, including the CT-100 sale. Several product agreements also require milestone payments, royalties or profit sharing. The filing reported no amounts due under specified related-party agreements at quarter-end.
Important facts for investors to verify
- Whether Biorphen commercialization began as expected, and the resulting sales, margins, supply arrangements and profit split with Sintetica.
- Actual cash burn and runway against management’s forecast, including the effect of the SWK facility’s interest, fees, amortization, security and covenants.
- FDA decisions, development timelines and remaining milestone obligations for the pipeline, particularly ET-105, DS-200, ET-104 and ET-203.
- Potential EM-100 milestone and royalty receipts, and the terms and economics of related-party product arrangements.
- Potential dilution from outstanding warrants, stock options and equity-plan awards; 17,807,167 common shares were outstanding as of October 31, 2019.